FiercePharma2d
Verona touts 'exceptionally strong' launch of blockbuster hopeful COPD treatment Ohtuvayre
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Expanded research on COPD and metabolic syndrome would advance patient-centered care, expert argues
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
News Medical on MSN17h
Addressing COPD and metabolic syndrome requires comprehensive research efforts
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...
pulmonologyadvisor1d
Benralizumab Improves Eosinophilic Exacerbations in Asthma, COPD
Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.
Study compares single-inhaler triple therapies for treatment of COPD
For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve ...
News Medical on MSN4d
Study finds no clinical advantage of budesonide inhaler over fluticasone in COPD
A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
GlobalData on MSN20h
AerWave Medical concludes study of ultrasound therapy for COPD
The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.
Fox News9d
19 drug approvals in 2024 that had 'big clinical impact,' according to GoodRx
2024 brought some major advancements in medicine. That includes the approval of "innovative" drugs like Tryvio for high blood pressure, Neffy for severe allergic reactions and Dupixent for chronic ...